Theragen Etex Co.Ltd (KQ:066700) — Market Cap & Net Worth
Market Cap & Net Worth: Theragen Etex Co.Ltd (066700)
Theragen Etex Co.Ltd (KQ:066700) has a market capitalization of $43.37 Million (₩64.00 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22508 globally and #1444 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theragen Etex Co.Ltd's stock price ₩2100.00 by its total outstanding shares 30476100 (30.48 Million). Also see 066700 current and non-current assets for a full breakdown of the balance sheet.
Theragen Etex Co.Ltd Market Cap History: 2015 to 2026
Theragen Etex Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $139.41 Million to $43.37 Million (-10.76% CAGR). Also see 066700 cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Theragen Etex Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$234.31 Billion | 0.02% | #704 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$234.31 Billion | 0.02% | #704 of 1384 |
Weight: Theragen Etex Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Theragen Etex Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theragen Etex Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Theragen Etex Co.Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Theragen Etex Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Theragen Etex Co.Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $120.41 Million | $101.28 Billion | $2.23 Billion | 0.00x | 0.05x |
| 2017 | $226.15 Million | $107.59 Billion | $1.27 Billion | 0.00x | 0.18x |
| 2018 | $214.79 Million | $117.47 Billion | -$10.22 Billion | 0.00x | N/A |
| 2019 | $173.07 Million | $138.08 Billion | $43.65 Billion | 0.00x | 0.00x |
| 2020 | $213.76 Million | $143.02 Billion | -$8.97 Billion | 0.00x | N/A |
| 2021 | $132.39 Million | $166.57 Billion | -$11.85 Billion | 0.00x | N/A |
| 2022 | $91.29 Million | $190.77 Billion | $9.56 Billion | 0.00x | 0.01x |
| 2023 | $92.32 Million | $216.47 Billion | $26.21 Billion | 0.00x | 0.00x |
| 2024 | $64.44 Million | $249.63 Billion | -$40.98 Billion | 0.00x | N/A |
| 2025 | $65.26 Million | $271.59 Billion | $10.60 Billion | 0.00x | 0.01x |
Competitor Companies of 066700 by Market Capitalization
Companies near Theragen Etex Co.Ltd in the global market cap rankings as of September 18, 2026. Review 066700 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Theragen Etex Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5605 globally with a market cap of $2.37 Billion USD ( ₩3.50 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8267 globally with a market cap of $1.16 Billion USD ( ₩1.71 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9464 globally with a market cap of $884.84 Million USD ( ₩1.31 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10523 globally with a market cap of $713.20 Million USD ( ₩1.05 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5605 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.37 Billion | ₩163500.00 |
| #8267 | ST Pharm Co.Ltd | KQ:237690 | $1.16 Billion | ₩91900.00 |
| #9464 | NatureCell Co.Ltd | KQ:007390 | $884.84 Million | ₩24600.00 |
| #10523 | Oscotec Inc | KQ:039200 | $713.20 Million | ₩37450.00 |
Theragen Etex Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Theragen Etex Co.Ltd's market cap moved from $139.41 Million to $ 43.37 Million, with a yearly change of -10.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩43.37 Million | -33.54% |
| 2025 | ₩65.26 Million | +1.28% |
| 2024 | ₩64.44 Million | -30.20% |
| 2023 | ₩92.32 Million | +1.13% |
| 2022 | ₩91.29 Million | -31.05% |
| 2021 | ₩132.39 Million | -38.07% |
| 2020 | ₩213.76 Million | +23.51% |
| 2019 | ₩173.07 Million | -19.42% |
| 2018 | ₩214.79 Million | -5.02% |
| 2017 | ₩226.15 Million | +87.82% |
| 2016 | ₩120.41 Million | -13.63% |
| 2015 | ₩139.41 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Theragen Etex Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.37 Million USD |
| MoneyControl | $43.37 Million USD |
| MarketWatch | $43.37 Million USD |
| marketcap.company | $43.37 Million USD |
| Reuters | $43.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theragen Etex Co.Ltd
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company wa… Read more